Gilead Patents Free Access to HIV Prevention Drug for Low-Resource Countries
Gilead Sciences has granted non-exclusive, royalty-free licenses to six generic manufacturers to produce and distribute lenacapavir in 120 low-income...
Jon Napitupulu
Biotheus and Immunoprecise Ink Material Transfer Agreement: A Promising Collaboration for Immunotherapy Advancement
ImmunoPrecise Antibodies and Biotheus have collaborated to develop bispecific therapies for solid tumors. Biotheus will evaluate Talem Therapeutics’ AI-enhanced...
Owkin and AstraZeneca Team Up to Triumph Over Breast Cancer
Owkin and AstraZeneca are collaborating on an AI-powered tool that will pre-screen for harmful mutations in breast cancer genes...
Advanced Prostate Cancer Breakthrough: Posluma Unlocks Hope and Extends Lives
Blue Earth Diagnostics, a renowned company in PET radiopharmaceutical development, announced the results of a post-hoc analysis from the...
Maze Therapeutics Pioneers Revolutionary Kidney Disease Treatment
Maze Therapeutics, a biopharmaceutical company, has commenced its Phase 1 clinical trial for MZE782, an oral small molecule therapy....
New ADHD Medication: Onyda XR Now Available in the US
ONYDA XR (clonidine hydrochloride), a groundbreaking liquid non-stimulant ADHD medication, has been released for commercial availability in the United...
Merck Acquires Novel B-Cell Depletion Therapy From Curon
Merck has acquired CN201, a bispecific antibody, from Curon Biopharmaceutical. This acquisition strengthens Merck’s pipeline for treating B-cell malignancies...
ENHERTU® Granted Priority Review in the U.S. for Patients Battling Metastatic Breast Cancer
Daiichi Sankyo and AstraZeneca‘s application for ENHERTU has been accepted for Priority Review by the US Food and Drug...
Biosimilar Otuli™ Receives FDA Approval: Encouraging News for Arthritis Patients
Fresenius Kabi, a subsidiary of Fresenius, and Formycon AG, a leading biosimilars developer, have received FDA approval for Otulfi™...
InCarda Phase 3 Trial Prematurely Terminated
InCarda Therapeutics has demonstrated promising results in developing FlecIH-103, an inhaled solution for converting paroxysmal atrial fibrillation (PAF) to...